Merck & Co. has signed an agreement with Marcadia Biotech, a startup firm based in Indianapolis, for the development and commercialization of diabetes treatments. Marcadia will remain independent and will receive an initial upfront fee, payments for exclusivity and continuing research, and also will be eligible for milestone and royalty payments.

Related Summaries